Regulatory – Alligator Bioscience

2025-01-22

Regulatory

Alligator Bioscience AB reports full year financial results for 2024 and for Q4 2024 and provides a business update

Sharpened focus on mitazalimab and cost-reduction program to maximize long-term value creation Announcement of rights issue of units of appr ...

2025-01-17

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-01-13

Regulatory

Today, on 13 January 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follow ...

2024-12-30

Regulatory

During the month of December, the number of shares and votes in Alligator Bioscience AB has changed due to conversion of a total of 170,681 ...

2024-12-20

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...

2024-12-13

Regulatory

13 December 2024 is the last day of trading in warrants series TO 9 in Alligator Bioscience AB (“Alligator Bioscience” or the &# ...

2024-12-04

Regulatory

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2025: Extraordinary General ...

2024-12-03

Regulatory

The board of directors of Alligator Bioscience AB (“Alligator”) has on 3 December 2024 resolved to convert 170,681 series C shar ...

2024-12-02

Regulatory

Alligator Bioscience AB (“Alligator” or the “Company”) hereby announces that the exercise price for warrants series ...